Twist Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2024 Annual Meeting of Stockholders held on February 6, 2024. The filing covers the voting outcomes for three proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Approximately 90.51% of eligible shares (52,300,164 shares) were present in person or by proxy. All three proposals were approved by stockholders:
- Proposal One (Election of Directors): Emily M. Leproust, Ph.D., and Robert Chess were elected as Class III Directors. Leproust received 33,957,330 votes for, while Chess received 27,503,789 votes for.
- Proposal Two (Executive Compensation): The non-binding advisory vote to approve Named Executive Officer compensation passed with 43,215,571 votes for and 2,904,714 votes against.
- Proposal Three (Auditor Ratification): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered accounting firm for the fiscal year ending September 30, 2024, with 52,195,318 votes for.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the final composition of the Board of Directors following the election of the two new Class III Directors.
- Confirm the level of shareholder support for executive compensation, noting that approximately 6.4% of votes cast were against the proposal.
- Review the full proxy statement for details on the specific compensation packages approved under Proposal Two.